A detailed history of Abrdn PLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Abrdn PLC holds 431,098 shares of SRPT stock, worth $45.1 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
431,098
Previous 329,845 30.7%
Holding current value
$45.1 Million
Previous $52.1 Million 3.32%
% of portfolio
0.1%
Previous 0.1%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$124.33 - $156.75 $12.6 Million - $15.9 Million
101,253 Added 30.7%
431,098 $53.8 Million
Q2 2024

Aug 09, 2024

BUY
$113.33 - $163.85 $15.6 Million - $22.6 Million
137,988 Added 71.92%
329,845 $52.1 Million
Q1 2024

May 08, 2024

BUY
$93.7 - $141.53 $4.22 Million - $6.37 Million
45,028 Added 30.67%
191,857 $24.8 Million
Q4 2023

Jan 31, 2024

BUY
$67.31 - $124.76 $9.88 Million - $18.3 Million
146,829 New
146,829 $14.2 Million
Q3 2021

Nov 15, 2021

SELL
$65.97 - $92.48 $333,280 - $467,208
-5,052 Closed
0 $0
Q2 2021

Aug 10, 2021

SELL
$69.38 - $86.75 $203,422 - $254,351
-2,932 Reduced 36.72%
5,052 $393,000
Q1 2021

May 06, 2021

BUY
$72.25 - $168.95 $17,195 - $40,210
238 Added 3.07%
7,984 $596,000
Q4 2020

Feb 10, 2021

BUY
$125.56 - $178.74 $26,995 - $38,429
215 Added 2.85%
7,746 $1.32 Million
Q3 2020

Oct 21, 2020

BUY
$127.12 - $172.34 $410,343 - $556,313
3,228 Added 75.02%
7,531 $1.06 Million
Q2 2020

Aug 10, 2020

SELL
$93.0 - $171.7 $6,417 - $11,847
-69 Reduced 1.58%
4,303 $690,000
Q1 2020

May 13, 2020

BUY
$82.38 - $131.64 $9,803 - $15,665
119 Added 2.8%
4,372 $428,000
Q4 2019

Feb 18, 2020

BUY
$76.53 - $135.58 $6,734 - $11,931
88 Added 2.11%
4,253 $549,000
Q3 2019

Nov 13, 2019

BUY
$72.81 - $156.91 $303,253 - $653,530
4,165 New
4,165 $314,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.